Skip to content

ENVERIC BIOSCIENCES, INC.: 10-Q filed 2026-08-14

What ENVERIC BIOSCIENCES, INC. reported in its quarterly report filed 2026-08-14 (fiscal Q2 2026): 31 published measures, 93 facts as tagged in accession 0001493152-26-038418.

This filing

Form
10-Q (quarterly report)
Filed
2026-08-14
Fiscal period
fiscal Q2 2026
Accession
0001493152-26-038418 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ENVERIC BIOSCIENCES, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2026-06-308,943,999USD
At 2025-12-315,095,941USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2026-06-308,082,524USD
At 2026-03-315,060,788USD
At 2025-12-314,177,541USD
At 2025-06-302,184,769USD
At 2025-03-313,917,713USD
At 2024-12-311,592,807USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-3,027,733USD91
2026-01-01 to 2026-06-30-4,661,206USD181
2026-01-01 to 2026-03-31-1,633,473USD90
2025-04-01 to 2025-06-30-2,519,181USD91
2025-01-01 to 2025-06-30-4,704,147USD181
2025-01-01 to 2025-03-31-2,184,966USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-4,701,378USD181
2025-01-01 to 2025-06-30-4,281,724USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2026-01-01 to 2026-06-308,348,207USD181
2025-01-01 to 2025-06-304,898,010USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2026-06-30-119,507,698USD
At 2025-12-31-114,846,492USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2026-04-01 to 2026-06-303,987,084shares91
2026-01-01 to 2026-06-302,743,993shares181
2025-04-01 to 2025-06-30216,311shares91
2025-01-01 to 2025-06-30182,590shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2026-04-01 to 2026-06-303,987,084shares91
2026-01-01 to 2026-06-302,743,993shares181
2025-04-01 to 2025-06-30216,311shares91
2025-01-01 to 2025-06-30182,590shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-0.76USD/shares91
2026-01-01 to 2026-06-30-1.7USD/shares181
2025-04-01 to 2025-06-30-11.65USD/shares91
2025-01-01 to 2025-06-30-25.76USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-0.76USD/shares91
2026-01-01 to 2026-06-30-1.7USD/shares181
2025-04-01 to 2025-06-30-11.65USD/shares91
2025-01-01 to 2025-06-30-25.76USD/shares181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2026-06-3081,929USD
At 2025-12-31159,234USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2026-01-01 to 2026-06-30213,787USD181
2025-01-01 to 2025-06-30400,108USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-3,027,441USD91
2026-01-01 to 2026-06-30-4,660,611USD181
2025-04-01 to 2025-06-30-2,519,049USD91
2025-01-01 to 2025-06-30-4,706,582USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2026-06-308,793,325USD
At 2025-12-314,936,707USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2026-06-30861,475USD
At 2025-12-31918,400USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2026-06-30682,794USD
At 2025-12-31581,020USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2026-04-01 to 2026-06-303,027,441USD91
2026-01-01 to 2026-06-304,660,611USD181
2025-04-01 to 2025-06-302,519,049USD91
2025-01-01 to 2025-06-304,706,582USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2026-04-01 to 2026-06-301,355,137USD91
2026-01-01 to 2026-06-301,701,106USD181
2025-04-01 to 2025-06-301,260,051USD91
2025-01-01 to 2025-06-302,006,422USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2026-06-303,935,884shares
At 2025-12-311,061,533shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2026-06-30128,145,545USD
At 2025-12-31119,593,456USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2026-06-30-594,681USD
At 2025-12-31-580,038USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2026-06-30723,249USD
At 2025-12-31675,552USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2026-06-30151,931USD
At 2025-12-31237,505USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2026-06-30497,029USD
At 2025-12-31259,216USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-3,027,733USD91
2026-01-01 to 2026-06-30-4,661,206USD181
2025-04-01 to 2025-06-30-2,519,181USD91
2025-01-01 to 2025-06-30-4,704,147USD181

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-3,035,358USD91
2026-01-01 to 2026-06-30-4,675,849USD181
2025-04-01 to 2025-06-30-2,494,708USD91
2025-01-01 to 2025-06-30-4,683,161USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2026-04-01 to 2026-06-301,635,478USD91
2026-01-01 to 2026-06-302,885,439USD181
2025-04-01 to 2025-06-301,219,018USD91
2025-01-01 to 2025-06-302,579,156USD181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2026-04-01 to 2026-06-3036,826USD91
2026-01-01 to 2026-06-3074,066USD181
2025-04-01 to 2025-06-3039,980USD91
2025-01-01 to 2025-06-3078,824USD181

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2025-01-01 to 2025-06-3042,180USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-292USD91
2026-01-01 to 2026-06-30-595USD181
2025-04-01 to 2025-06-30-132USD91
2025-01-01 to 2025-06-302,435USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2026-01-01 to 2026-06-301,291,038USD181
2025-01-01 to 2025-06-30578,499USD181

Inspect the source

Entity
ENVERIC BIOSCIENCES, INC. / CIK 0000890821
Captured
2026-09-20T05:03:46.618Z
SEC response SHA-256
ed23dbf99f9ce404ef7949b5b1b4b3a643f25caca94a6c8cd8444309157de101

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000890821.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))